Berlock ApS

Use of metallic gold as a non-toxic immune suppressor

AUROMEDICATION

Involves

Bio-release of gold ions from gold implants

Berlock ApS is a Research & Development Company with activities in the field of biomedical technology. The company has close connections to universities and research institutes.

       Our specific field of interest is the application of millimetre and > 20 micron seized gold implants as local providers of gold ions in a biomedical context. Focus is on the treatment of inflammation, the third fastest growing therapeutic area.   Berlock own several patents dealing with the use of gold implants as a provider of curative gold ions.

       A substantial scientific literature, on the treatment of rheumatic diseases with gold ion containing drugs like Myocrisin® has indisputably shown that gold ions suppress inflammation. There exist thus clear proofs for gold ions being curative.

       When gold implants are used as providers of gold ions the treatment is local, i.e. no spread to the rest of the body. Gold ions are only found in a mm narrow 3D zone around the implant.

       In noninflamed tissue a gold implant will continue to release tiny amounts of gold ions (i.e. dicyanoaurate ions). This state could be called the resting stage, but if the locality are or become inflamed the amount of bio-released gold ions will grow because of the local raise in  number of macrophages.  ‘Gold implant therapy’ – Auromedication -   is a safe way of treating locale/regional autoimmune maladies, and it is without known side effects.